• Vanita Noronha, George Abraham, Vijay Patil, Amit Joshi, Nandini Menon, Abhishek Mahajan, Amit Janu, Srushti Jain, Vikas T Talreja, Akhil Kapoor, Gunjesh Kumar Singh, Satvik Khaddar, Kushal Gupta, Narmadha Rathinasamy, Sujay Srinivas, Amit Agrawal, Pradeep Ventrapati, and Kumar Prabhash.
• Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
• Cancer Med. 2021 Mar 1; 10 (5): 1525-1534.

BackgroundCheckpoint inhibitors (Nivolumab and Pembrolizumab) are approved for multiple indications in solid tumors. However access to these therapies is limited in low and middle income countries. Hence we performed an audit to identify accessibility, adverse event rates, compliance, progression free survival and overall survival in solid tumors.MethodsThis was a single center retrospective analysis of prospective data base of patients with non-melanoma solid tumors who were treated with immunotherapy from August 2015 to November 2018. Adverse events during immunotherapy were documented and graded using CTCAE (Common terminology criteria for adverse events), v. 4.02. The response rates to immunotherapy, toxicities and the time to onset and resolution of toxicities were also evaluated as secondary endpoints.ResultsOut of 9610 patients, only 155 patients (1.61%) could receive immunotherapy. The most common malignancies included metastatic non-small cell lung cancer, metastatic renal cell carcinoma, metastatic urothelial carcinoma and relapsed/recurrent head and neck squamous cell carcinoma. Median overall survival in patients who received immunotherapy in non-melanoma solid malignancies was 5.37 months (95% CI, 3.73-9.73). Poor performance status at baseline was the only adverse prognostic factor. The median progression free survival was 2.57 months (95% CI, 1.73-3.83). Immunotherapy was well tolerated with most common side effects being fatigue 14.8% and anorexia 5.8%. The cumulative incidence of immune related adverse events like hepatitis, pneumonitis, colitis and nephritis was less than 10%.ConclusionReal-world data in Indian setting confirms the benefit of immunotherapy in patients with advanced non-melanoma solid tumors.© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

55 keywords...

hide…